Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 59Colorectal Neoplasms 45Rectal Neoplasms 35Stomach Neoplasms 27Pancreatic Neoplasms 27Neoplasm Metastasis 24Neoplasms 19Colonic Neoplasms 18Triple Negative Breast Neoplasms 7Esophageal Neoplasms 6Adenocarcinoma 6Liver Neoplasms 5Brain Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Head and Neck Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Unknown Primary 2Melanoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma 2Breast Neoplasms, Male 2

Interventions

Trastuzumab 4pertuzumab 2Docetaxel 2palbociclib 1Protons 1Paclitaxel 1Letrozole 1Fulvestrant 1Enfuvirtide 1Doxorubicin 1Cyclophosphamide 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HER2-positive Breast Cancer × Capecitabine × Clear all
NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

National Cancer Centre, Singapore

Phase 2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡